Elite Discovery provides clinicians with one of the market’s most comprehensive and accurate Next Generation Sequencing (NGS) based testing solution for the identification of clinically actionable mutations and the discovery of novel variants with important functions in cancer.
The panel offers whole exon coverage of 689 cancer-related genes and interrogates the most common types of alterations, including SNVs, indels, CNVs and fusions in solid tumours.
Gene Panel Overview
Advantages
-
Whole exon coverage of 689 cancer-related genes, supporting most common types of genomic alterations including base substitutions, TMB and MSI. Includes genes associated with both sporadic and hereditary cancers.
-
Provides interpretation on the theapeutic relevance in 300+ drugs, including 360 targeted therapies (both approved and currently in clinical trials). 11 immunotherapies and 11 commonly used chemotherapies.
-
Includes 425 genes in cancer-related pathways for discovery of novel pathogenic variants.
Comprehensive
-
The median adequate sequencing depth is up to 900x using tissue samples.
Reliable
-
Elite Discovery (Tissue) : matched FFPE and Peripheral Blood.
-
Sample Requirements: >15-20 FFPE 10mm*10mm (5-10um) sections and 3-5mL of Peripheral Blood.
-
TAT: 10 Working Days
Simple
689 Gene List
(single nucleotide variation, short insertion or deletion variation)
